{
    "General": {
        "Code": "ON4",
        "Type": "Common Stock",
        "Name": "ONO PHARMACEUT.",
        "Exchange": "F",
        "CurrencyCode": "EUR",
        "CurrencyName": "Euro",
        "CurrencySymbol": "\u20ac",
        "CountryName": "Germany",
        "CountryISO": "DE",
        "OpenFigi": null,
        "ISIN": "JP3197600004",
        "LEI": null,
        "PrimaryTicker": "4528.TSE",
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "March",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Drug Manufacturers-General",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Pharmaceuticals",
        "GicSubIndustry": "Pharmaceuticals",
        "Description": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 3761,
        "UpdatedAt": "2023-08-31"
    },
    "Highlights": {
        "MarketCapitalization": 8611885056,
        "MarketCapitalizationMln": 8611.8851,
        "EBITDA": 170909007872,
        "PERatio": 11.4189,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": 1561.405,
        "DividendShare": 70,
        "DividendYield": 0.0319,
        "EarningsShare": 1.48,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": 0,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": "2023-06-30",
        "ProfitMargin": 0.2499,
        "OperatingMarginTTM": 0.3328,
        "ReturnOnAssetsTTM": 0.1171,
        "ReturnOnEquityTTM": 0.1593,
        "RevenueTTM": 460481003520,
        "RevenuePerShareTTM": 942.986,
        "QuarterlyRevenueGrowthYOY": 0.125,
        "GrossProfitTTM": 267850000000,
        "DilutedEpsTTM": 1.48,
        "QuarterlyEarningsGrowthYOY": 0.079
    },
    "Valuation": {
        "TrailingPE": 11.4189,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": -105193152512,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 488334016,
        "SharesFloat": 398807697,
        "PercentInsiders": 15.984000000000002,
        "PercentInstitutions": 46.059,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": 0.3562,
        "52WeekHigh": 24.6,
        "52WeekLow": -13.9,
        "50DayMA": 16.618,
        "200DayMA": 18.9725,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0.54,
        "ForwardAnnualDividendYield": 0.0319,
        "PayoutRatio": 0.2971,
        "DividendDate": null,
        "ExDividendDate": "2023-09-28",
        "LastSplitFactor": null,
        "LastSplitDate": null,
        "NumberDividendsByYear": {
            "0": {
                "Year": 2022,
                "Count": 2
            },
            "1": {
                "Year": 2023,
                "Count": 1
            }
        }
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}